US2004147537A1PendingUtilityA1

Method for treating cancer with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof

Individually held — no corporate assignee on recordPriority: Nov 6, 1989Filed: Jul 28, 2003Published: Jul 29, 2004
Est. expiryNov 6, 2009(expired)· nominal 20-yr term from priority
A61K 9/7023A61K 31/47A61K 31/4745
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating specific forms of cancer with water-insoluble 20(S)-camptothecin compounds with the closed-lactone ring intact and/or derivatives thereof is disclosed. The method includes administering the compounds intramuscularly, orally and transdermally.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating or retarding a malignant tumor in a mammal comprising administering subcutaneously to said mammal in need of such treatment an effective amount of a water-insoluble compound with a closed-lactone ring wherein said malignant tumor is selected from the group consisting of breast cancer, colon cancer, lung cancer, stomach cancer, ovarian cancer, pancreas cancer, prostate cancer, osteosarcoma, melanoma, and bladder cancer; 
 and wherein said compound is selected from the group consisting of 20(S)-camptothecin, 9-nitro-20(S)-camptothecin, 9-amino-20 (S)-camptothecin, dimethylaminomethyl-10-hydroxy-20(S)-camptothecin (topotecan), 7-ethyl-10-carbonyloxy-camptothecin (camptothecin-11), 7-ethyl-10-hydroxy-20(S)-camptothecin, 10,11-methylenedioxy-20(S)-camptothecin, 9-chloro-20(S)-camptothecin, 9-bromo-20(S)-camptothecin, 9-hydroxy-20(S)-camptothecin, 11-hydroxy-20(S)-camptothecin, 10-hydroxy-20(S)-camptothecin, and mixtures thereof.    
     
     
         2 . The method according to  claim 1 , wherein said compound is selected from the group consisting of 20(S)-camptothecin, 9-Nitro-20(S)-camptothecin and 9-Amino-20(S)-camptothecin.  
     
     
         3 . The method according to  claim 1 , wherein said effective amount is from about 1 mg/per kg of body weight twice a week to about 4 mg/per kg of body weight twice a week in mice.  
     
     
         4 . The method according to  claim 1 , wherein said effective amount is administered daily from about 0.75 mg/per kg to about 1.5 mg/per kg in mice.  
     
     
         5 . The method according to  claim 1 , wherein said effective amount is from about 12.5 mg/m 2  of body surface per day to about 31.3 mg/m 2  of body surface per day in humans.  
     
     
         6 . The method of  claim 1 , wherein said compound is 20(S)-camptothecin.  
     
     
         7 . The method, of  claim 1 , wherein said compound is 9-nitro-20(S)-camptothecin.  
     
     
         8 . The method of  claim 1 , wherein said compound is 9-amino-20(S)-camptothecin.  
     
     
         9 . The method of  claim 1 , wherein said compound is 9-nitro-20(S)-camptothecin and said malignant tumor is breast cancer.

Join the waitlist — get patent alerts

Track US2004147537A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.